收费全文 | 188933篇 |
免费 | 32694篇 |
国内免费 | 2557篇 |
耳鼻咽喉 | 5458篇 |
儿科学 | 6059篇 |
妇产科学 | 3001篇 |
基础医学 | 7975篇 |
口腔科学 | 2471篇 |
临床医学 | 29099篇 |
内科学 | 56580篇 |
皮肤病学 | 8028篇 |
神经病学 | 17496篇 |
特种医学 | 7673篇 |
外科学 | 47980篇 |
综合类 | 406篇 |
现状与发展 | 72篇 |
预防医学 | 8225篇 |
眼科学 | 3773篇 |
药学 | 3771篇 |
中国医学 | 138篇 |
肿瘤学 | 15979篇 |
2024年 | 700篇 |
2023年 | 4954篇 |
2022年 | 1545篇 |
2021年 | 3733篇 |
2020年 | 6374篇 |
2019年 | 2656篇 |
2018年 | 8012篇 |
2017年 | 7814篇 |
2016年 | 8963篇 |
2015年 | 9060篇 |
2014年 | 16307篇 |
2013年 | 16558篇 |
2012年 | 7032篇 |
2011年 | 7153篇 |
2010年 | 11262篇 |
2009年 | 14981篇 |
2008年 | 7278篇 |
2007年 | 5634篇 |
2006年 | 8064篇 |
2005年 | 5420篇 |
2004年 | 4718篇 |
2003年 | 3616篇 |
2002年 | 3736篇 |
2001年 | 5428篇 |
2000年 | 4600篇 |
1999年 | 4726篇 |
1998年 | 4170篇 |
1997年 | 3886篇 |
1996年 | 3736篇 |
1995年 | 3546篇 |
1994年 | 2267篇 |
1993年 | 1853篇 |
1992年 | 2358篇 |
1991年 | 2332篇 |
1990年 | 1859篇 |
1989年 | 2065篇 |
1988年 | 1777篇 |
1987年 | 1542篇 |
1986年 | 1620篇 |
1985年 | 1389篇 |
1984年 | 978篇 |
1983年 | 897篇 |
1982年 | 703篇 |
1981年 | 587篇 |
1980年 | 492篇 |
1979年 | 617篇 |
1978年 | 571篇 |
1977年 | 604篇 |
1975年 | 485篇 |
1972年 | 458篇 |
Background
On April 1, 2016, the Ministerial ordinance was enforced, and musculoskeletal examination of the extremities was made mandatory. From 2008, the University of us started musculoskeletal direct examination. To expand the examination, from 2016, we started to use the marksheet-type questionnaire. This study aimed to report the results of a musculoskeletal examination and investigate the association between musculoskeletal examination and age/gender and reports the reliability of the collected questionnaire data.Methods
Direct musculoskeletal examination was performed in K school by 7 orthopedic surgeons. A marksheet-type screening questionnaire was distributed to all the elementary and junior high school students in Tsukuba and Hitachiomiya cities. The rates of abnormal findings for scoliosis, standing flexion, full squatting with the heels on the floor, general joint laxity, and standing on one leg, torticollis, and flat feet were calculated. We compared the results of the questionnaire and direct examination and calculated sensitivity, specificity, and odds ratio.Results
A total of 1844 students in K school had direct examination, and 22,494 questionnaires were able to correct in Tsukuba and Hitachiomiya cities. The rates of abnormal findings in direct examination/questionnaire in scoliosis, standing flexion, full squat, general joint laxity, standing on one leg, torticollis and flat foot were 18.7% (344/1842)/5.1% (1094/21441), 20.2% (372/1841)/26.6% (5817/22078), 6.2% (114/1832)/6.9% (1516/22101), 7.5% (1648/22252), 4.9% (1100/22077), 2.2% (31/1844)/1.2% (272/21687), and 12.5% (231/1842)/8.7% (1785/20871), respectively. Sensitivities of the questionnaire for scoliosis, stand flexion, full squatting, torticollis, and flat feet were 16.8% (53/316), 67.9% (250/368), 48.2% (55/114), 18.9% (7/37), and 32.2% (65/202), respectively.Conclusion
We reported the result of musculoskeletal examination. Accuracy and reliability of this questionnaire were not satisfactory. To perform high quality musculoskeletal examinations, we will aim to increase the quality of screening methods. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.